Intra Cellular Therapies | ITCI - Дебиторская задолженность



Дебиторская задолженность Изменить Дата
Acadia Pharmaceuticals USD 148.23M 8.79M 2025-12
ALKERMES USD 334.02M 21.08M 2025-12
BioCryst Pharmaceuticals USD 106.82M 15.49M 2025-12
Biogen USD 1.79B 76.6M 2026-03
Bristol-Myers Squibb USD 14.36B 164M 2026-03
Cytokinetics USD 1.81M 6.6M 2025-09
Esperion Therapeutics USD 140.19M 21.21M 2025-12
Gilead Sciences USD 4.91B 182M 2025-12
Halozyme Therapeutics USD 441.27M 95.24M 2025-12
J&J USD 21.33B 3.72B 2025-12
Nektar Therapeutics USD 1.78M 1.12M 2025-12
Neurocrine Biosciences USD 686.8M 41.2M 2025-12
Novartis USD 12.29B 3.3B 2025-12
Prothena USD 5.16M 0 2023-12
RedHill Biopharma USD 5.35M 1.78M 2025-06
Supernus Pharmaceuticals USD 187.8M 16.55M 2025-12
United Therapeutics USD 350.2M 52.5M 2025-12
Vanda Pharmaceuticals USD 47.1M 4.35M 2024-12